<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05047029</url>
  </required_header>
  <id_info>
    <org_study_id>282/18_1</org_study_id>
    <nct_id>NCT05047029</nct_id>
  </id_info>
  <brief_title>Myocardial Fibrosis and Inflammation in Liver Cirrhosis</brief_title>
  <official_title>Multiparametric Magnetic Resonance Imaging in Patients With Liver Cirrhosis for Evaluation of Myocardial Fibrosis and Inflammation in Cirrhotic Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this clinical prospective study is to assess structural and functional myocardial&#xD;
      changes in patients with liver cirrhosis after implantation of transjugular intrahepatic&#xD;
      portosystemic shunt (TIPS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2, 2018</start_date>
  <completion_date type="Actual">September 8, 2021</completion_date>
  <primary_completion_date type="Actual">January 5, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial T1 relaxation time</measure>
    <time_frame>Change after 1 year of transjugular intrahepatic portosystemic shunt insertion.</time_frame>
    <description>T1 relaxation times will be obtained to asses acute myocardial injury and fibrosis. T1 maps will be analyzed using a segmental approach by region of interest analysis. T1 relaxation times are given in [ms].</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial T2 relaxation time</measure>
    <time_frame>Change after 1 year of transjugular intrahepatic portosystemic shunt insertion.</time_frame>
    <description>T2 relaxation times will be obtained to asses myocardial edema. T2 maps will be analyzed using a segmental approach by region of interest analysis. T2 relaxation times are given in [ms].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial ECV</measure>
    <time_frame>Change after 1 year of transjugular intrahepatic portosystemic shunt insertion.</time_frame>
    <description>Myocardial extracellular volume will be obtained to asses extracellular space/myocardial fibrosis. ECV values will be calculated using a segmental approach by region of interest analysis of native and contrast-enhanced T1 relaxation maps. ECV values are given in [%].</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">13</enrollment>
  <condition>Cirrhosis, Liver</condition>
  <condition>Cardiomyopathies</condition>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>Patients with cirrhosis</arm_group_label>
    <description>Patients with cirrhosis and transjugular intrahepatic portosystemic shunt implantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transjugular intrahepatic portosystemic shunt implantation</intervention_name>
    <description>Transjugular intrahepatic portosystemic shunt is an artificial channel within the liver that establishes communication between the inflow portal vein and the outflow hepatic vein. It is used to treat portal hypertension (e.g., in liver cirrhosis)</description>
    <arm_group_label>Patients with cirrhosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Magnetic resonance imaging</intervention_name>
    <description>Multiparametric cardiac and hepatic magnetic resonance imaging</description>
    <arm_group_label>Patients with cirrhosis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic (Department of Internal Medicine I, University Hospital Bonn, Germany)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  liver cirrhosis with evaluation of TIPS implantation&#xD;
&#xD;
          -  patients who are 18 years of age or older&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  underlying cardiac disease, e.g. known myocardial infarction, previous myocarditis,&#xD;
             congenital heart disease, cardiomyopathies of other causes known underlying disease&#xD;
             witt potential cardiac involvement, e.g. storage disease (e.g. hemochromatosis, Fabry&#xD;
             disease), inflammatory (e.g. sarcoidosis), endocrinological (e.g. diabetes mellitus,&#xD;
             hyper-/hypothyroidism), autoimmune (e.g. systemic lupus erythematosus,&#xD;
             dermatomyositis, rheumatoid arthritis), therapeutic (chemotherapy).&#xD;
&#xD;
          -  patients with contraindication for contrast-enhanced MRI&#xD;
&#xD;
          -  pregnant and breastfeeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Bonn, Clinic for Diagnostic and Interventional Radiology</name>
      <address>
        <city>Bonn</city>
        <state>NRW</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Bonn, Medical Clinic and Polyclinic I</name>
      <address>
        <city>Bonn</city>
        <state>NRW</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Isaak A, Praktiknjo M, Jansen C, Faron A, Sprinkart AM, Pieper CC, Chang J, Fimmers R, Meyer C, Dabir D, Thomas D, Trebicka J, Attenberger U, Kuetting D, Luetkens JA. Myocardial Fibrosis and Inflammation in Liver Cirrhosis: MRI Study of the Liver-Heart Axis. Radiology. 2020 Oct;297(1):51-61. doi: 10.1148/radiol.2020201057. Epub 2020 Aug 18.</citation>
    <PMID>32808886</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 8, 2021</study_first_submitted>
  <study_first_submitted_qc>September 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Julian Alexander Luetkens</investigator_full_name>
    <investigator_title>Prinicipal Investigator, Senior Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

